Abstract
Denosumab, a human monoclonal antibody that binds to and neutralizes the receptor activator of nuclear factor-? ligand (RANKL), has recently become available for the prevention of skeletal-related events (SRE) of bone metastases from breast cancer. In a recent study, denosumab was shown to be more effective than zoledronic acid in delaying SRE, and it has been shown that hypocalcemia occurred more frequently and renal failure less frequently, in patients treated with denosumab as compared to those treated with zoledronic acid. In light of these studies, we used denosumab to successfully treat a patient presenting with acute renal failure caused by a tumor-related hypercalcemia arising from breast cancer bone metastases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
